Schizophreniform Disorders Clinical Trial
Official title:
Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy (I-CAT)
To test the feasibility of a clinical trial implementing I-CAT, a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life) for 40 people with first episode psychosis in the context of a small randomized controlled trial.
Schizophrenia is one of the most devastating disorders that often results in a lack of functional recovery. Current treatments focused on remediating symptoms have shown only small successes in a return to functioning despite evidence of a dysregulated stress response. There is a fundamental gap in understanding the impact of allostatic overload in persons with schizophrenia that the investigators theorize is associated with deficits in functioning and with an increased vulnerability and relapse risk. The long-term goal is to test an intervention aimed at improving stress reactivity. The objective in this application is to develop and test the feasibility of a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping. The central hypothesis is that an intervention that improves stress reactivity as measured proximally by endocrine, immune, and autonomic indices will result in improved adaptive capacity, better role functioning, reduced risk of relapse, and decreased likelihood of disability for people in the early stages of schizophrenia. The rationale for the proposed research is that stress reactivity may be a modifiable risk factor underlying functional deficits in schizophrenia. The intervention integrates two treatment approaches. The first is based on research showing that mindfulness meditation practice is associated with alterations in the neural processing of stressful events and targets adaptive responses to stress. The second focuses on providing a buffer against stress by using the self-generation of adaptive emotions with a positive psychology intervention, which is potentially associated with building protective social resources. These complimentary interventions provide a comprehensive synergistic approach for this population that could lead to more adaptive coping responses and create a buffer against stress ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Completed |
NCT00419146 -
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05974527 -
Pilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
|
Phase 4 | |
Recruiting |
NCT06423651 -
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
|
N/A | |
Recruiting |
NCT04113993 -
Bazedoxifene -Treatment for Women With Schizophrenia
|
Phase 4 | |
Completed |
NCT06041646 -
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
|
Phase 4 | |
Completed |
NCT04418011 -
Neuromodulation of Social Cognitive Circuitry in People With Schizophrenia Spectrum Disorders
|
N/A | |
Active, not recruiting |
NCT05658510 -
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
|
Phase 3 | |
Terminated |
NCT00515489 -
Study on the Safety and Effectiveness of Risperidone Treatment of Acute Psychotic Patients
|
N/A | |
Recruiting |
NCT05877716 -
EPI-MINN: Targeting Cognition and Motivation - National
|
N/A | |
Completed |
NCT03079024 -
Minnesota Community-Based Cognitive Training in Early Psychosis
|
N/A | |
Completed |
NCT03559426 -
Research Into Antipsychotic Discontinuation and Reduction Trial
|
Phase 4 | |
Recruiting |
NCT05756855 -
Young Adults With Violent Behavior During Early Psychosis
|
N/A | |
Recruiting |
NCT04497857 -
Academic-Community EPINET (AC-EPINET)
|
N/A | |
Recruiting |
NCT05109065 -
Peripheral Immune System in Individuals With Schizophrenia
|
||
Completed |
NCT03187769 -
Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder
|
Phase 3 | |
Recruiting |
NCT03632278 -
Mindfulness Psychoeducation Program for Schizophrenia
|
N/A | |
Completed |
NCT01082588 -
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
|
Phase 4 | |
Recruiting |
NCT05538832 -
Remote State Representation in Early Psychosis
|
Early Phase 1 | |
Recruiting |
NCT06002958 -
Horyzons: Implementation and Integration in Clinical Practice
|
N/A |